Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Oliva

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 10, 2026
Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC studyLara Iglesias Docampo, Neus Basté, Marc Oliva, et al.
Oral Oncology|February 21, 2026
An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion)Panagiota Economopoulou, Abraham Pouliakis, Miltiades Kyprianou, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Integration of Patient-Reported Outcome Measures in Clinical Practice for Head and Neck Cancer Patients: A Cross-Sectional SurveyTatiana Dragan, Niclas Hubel, Jens Lehmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2026
Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO projectPaula Sàbat, Maria Ajenjo-Bauza, Cinta Hierro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyBarbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2026
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trialHye Ryun Kim, Marc Oliva, Sebastien Salas, et al.
The New England Journal of Medicine|June 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Robert I Haddad, Yungan Tao, et al.
International Journal of Radiation Oncology, Biology, Physics|April 26, 2025
Accuracy and Prognosis of Extranodal Extension on Radiologic Imaging in Human Papillomavirus-Mediated Oropharyngeal Cancer: a Head and Neck Cancer International Group (HNCIG) real-world studyHisham Mehanna, Ahmad K Abou-Foul, Christina Henson, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|May 10, 2026
Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC studyLara Iglesias Docampo, Neus Basté, Marc Oliva, et al.
Oral Oncology|February 21, 2026
An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion)Panagiota Economopoulou, Abraham Pouliakis, Miltiades Kyprianou, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Nature Communications|August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityS Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Integration of Patient-Reported Outcome Measures in Clinical Practice for Head and Neck Cancer Patients: A Cross-Sectional SurveyTatiana Dragan, Niclas Hubel, Jens Lehmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2026
Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO projectPaula Sàbat, Maria Ajenjo-Bauza, Cinta Hierro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyBarbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2026
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trialHye Ryun Kim, Marc Oliva, Sebastien Salas, et al.
The New England Journal of Medicine|June 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Robert I Haddad, Yungan Tao, et al.
International Journal of Radiation Oncology, Biology, Physics|April 26, 2025
Accuracy and Prognosis of Extranodal Extension on Radiologic Imaging in Human Papillomavirus-Mediated Oropharyngeal Cancer: a Head and Neck Cancer International Group (HNCIG) real-world studyHisham Mehanna, Ahmad K Abou-Foul, Christina Henson, et al.
Pageof 7